Why the FDA’s CAR-T approval sends strong signal to cell therapy industry: an interview with Martin Lamb
In this interview, Martin Lamb, TrakCel, discusses the recent FDA approval of Novartis’ CAR-T cell therapy.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.